We conducted a retrospective study to assess the outcomes of capecitabine for advanced breast cancer (ABC) after perioperative fluoropyrimidines (FPs).
The charts of patients with ABC who received capecitabine between 2008 and 2016 at the National Cancer Center Hospital (Tokyo, Japan) were reviewed. Progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs) were compared between two groups: an FP group (prior perioperative FP use) and a non-FP group (no prior FP use).
Overall, 288 patients (FP n = 105; non-FP n = 183) were analyzed. The two groups had similar patient characteristics. The FP group had significantly poorer PFS than the non-FP group (multivariate hazard ratio [HR] 1.33; 95% confidence interval [CI] 1.02–1.73; p = 0.036), although the OS did not differ significantly between the groups (multivariate HR 1.00; 95% CI 0.67–1.50; p = 0.994). With different cut-off values (relapse-free interval [RFI] = 3, 4, and 5 years), multivariate HRs for PFS were 1.32–1.67 (short RFI), and 1.00–1.25 (long RFI). A trend for a larger HR in the FP group compared to the non-FP group with short RFI than in that with long RFI was also seen for OS. Response rate (RR) and disease control rate (DCR) did not differ significantly between the groups (RR in FP vs non-FP 13.8 vs 21.0%; p = 0.173; DCR 54.0 vs 59.9%; p = 0.418). No significant difference in AEs existed between the groups.
Extra caution is needed when capecitabine is considered for patients with ABC who used perioperative FP, especially those who had early recurrence.
Supplementary material 1 (PPTX 40 KB)280_2018_3617_MOESM1_ESM.pptx
Supplementary material 2 (DOCX 30 KB)280_2018_3617_MOESM2_ESM.docx
Supplementary material 3 (DOCX 33 KB)280_2018_3617_MOESM3_ESM.docx
Supplementary material 4 (DOCX 30 KB)280_2018_3617_MOESM4_ESM.docx
Supplementary material 5 (DOCX 27 KB)280_2018_3617_MOESM5_ESM.docx
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE (2014) Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(29):3307–3329. https://doi.org/10.1200/jco.2014.56.7479CrossRefPubMed
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485–493. https://doi.org/10.1200/jco.19188.8.131.525CrossRefPubMed
Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Luck HJ (2003) Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14(8):1227–1233 CrossRefPubMed
Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, Namer M (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40(4):536–542. https://doi.org/10.1016/j.ejca.2003.11.007CrossRefPubMed
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543. https://doi.org/10.1007/s10549-007-9885-0CrossRefPubMed
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799 CrossRefPubMed
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594–601. https://doi.org/10.1200/JCO.2013.52.4892CrossRefPubMedPubMedCentral
Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, Takahashi M, Takagi M, Tokunaga Y, Fukushima R, Munakata Y, Nishikawa K, Takagane A, Tanaka T, Sekishita Y, Sakamoto J, Tsuburaya A (2012) Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer 15(3):245–251. https://doi.org/10.1007/s10120-011-0101-xCrossRefPubMed
Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K (2003) European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 9(1):143–150 PubMed
Takashima A, Shirao K, Hirashima Y, Takahari D, Okita N, Akatsuka S, Nakajima TE, Matsubara J, Yasui H, Asakawa T, Kato K, Hamguchi T, Muro K, Yamada Y, Shimada Y (2008) Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus 21(7):607–611. https://doi.org/10.1111/j.1442-2050.2008.00821.xCrossRefPubMed
Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, Kuroi K, Im S-A, Park B-W, Kim S-B, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park K-H, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645CrossRefPubMed
Food US, Administration D (2016) Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020896s039lbl.pdf. Accessed 16 Aug 2017
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026CrossRefPubMed
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4(11):e7695. https://doi.org/10.1371/journal.pone.0007695CrossRefPubMedPubMedCentral
Natori A, Ethier JL, Amir E, Cescon DW (2017) Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 77:40–47. https://doi.org/10.1016/j.ejca.2017.02.024CrossRefPubMed
- Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
- Springer Berlin Heidelberg
- Cancer Chemotherapy and Pharmacology
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
Neu im Fachgebiet Onkologie
Mail Icon II